Delcath Systems Inc (DCTH)

[m_maker]

It has anyways been known that their system was intended to treat extremely rare disease. There maybe few patients, but they do want to live, so price can be negotiate to compensate for a small market. The good thing about percutaneous hepatic perfusion is that it can be used in other indications besides ocular melanoma cause liver cancer. This is especially important in other markets that have less strict rules about usage. For delcath to survive they need to expand into all of these markets. Moving into Brazil is a good step. Back in the day delcath had an agreement to sell to the Asian market under the condition that it get accepted into the us market first. So if they do ever manage to get FDA approved than the whole world will open up to them. This has all been good news for them. The more people they treat the more information they have for FDA even if it comes from outside the US, and their recent deal takes a lot of pressure off fronting the cost of clinical trials. Anyway, that's my opinion on the situation.